Show simple item record

dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorKınıkoğlu, Oğuzcan
dc.contributor.authorHelvacı Yılmaz, Nesrin
dc.contributor.authorBilici, Ahmet Erkan
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorŞeker, Mesut Metin
dc.contributor.authorÇakır, Tansel
dc.contributor.authorYıldız, Özcan
dc.contributor.authorHamdard, Jamshid
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:47Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:47Z
dc.date.issued2019en_US
dc.identifier.citationÖlmez, Ö. F., Kınıkoğlu, O., Helvacı Yılmaz, N., Bilici, A. E., Çubukçu, E., Şeker, M. M. … Hamdard, J. (2019). Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade. Journal of Oncology Pharmacy Practice, 25(6), 1526-1530. https://dx.doi.org/10.1177/1078155218792672en_US
dc.identifier.issn1078-1552
dc.identifier.urihttps://hdl.handle.net/20.500.12511/945
dc.identifier.urihttps://dx.doi.org/10.1177/1078155218792672
dc.description.abstractParaneoplastic neurological syndrome is associated with anti-Ri antibodies, which are typically present with opsoclonus–myoclonus–ataxia. Human epidermal growth factor receptor 2 (HER2) overexpression is present in 15%–25% of breast cancer and is associated with poor prognosis. There are a few reports of paraneoplastic neurological syndrome associated with HER2-positive breast cancer in the literature, of which most are anti-Yo-associated paraneoplastic neurological syndrome. We present herein the case of a female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome. Following the diagnosis of paraneoplastic syndrome, chemotherapy with dual HER2 blockade and immunomodulating treatment including intravenous immunoglobulin and oral prednisolone were administered. Although the patient was negative for serum anti-Ri antibodies, there was partial clinical improvement and her neurological deficit persisted. To our knowledge, this is the first case report of female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome and treated with dual HER2 blockade.en_US
dc.language.isoengen_US
dc.publisherSAGE Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectHER2 Blockadeen_US
dc.subjectOpsoclonus–Myoclonus Syndromeen_US
dc.subjectParaneoplastic Neurological Syndromeen_US
dc.titleAnti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockadeen_US
dc.typearticleen_US
dc.relation.ispartofJournal of Oncology Pharmacy Practiceen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyoloji Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalıen_US
dc.authorid0000-0001-7566-1063en_US
dc.authorid0000-0002-7685-2766en_US
dc.identifier.volume25en_US
dc.identifier.issue6en_US
dc.identifier.startpage1526en_US
dc.identifier.endpage1530en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1177/1078155218792672en_US
dc.identifier.wosqualityQ4en_US
dc.identifier.scopusqualityQ3en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record